ReviewDialogues in health2026
Early mineralocorticoid receptor antagonism for end-organ protection in hypertension: Implications for disparities and rethinking the timing paradigm.
Review in Dialogues in health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: Hypertension-related end-organ damage disproportionately affects Black populations, with earlier onset, greater severity, and higher rates of heart failure and chronic kidney disease despite treatment. Because structural injury may persist even when blood-pressure (BP) targets are met, this review examines aldosterone-mineralocorticoid receptor (MR) signaling as a driver of residual tissue injury and develops a hypothesis-generating framework for earlier, risk-stratified MR antagonism. Methods: This is a narrative review. We searched PubMed/MEDLINE and the Cochrane Library (inception-July 2026) using terms including mineralocorticoid receptor antagonist, aldosterone, spironolactone, eplerenone, finerenone, hypertension, resistant hypertension, end-organ damage, fibrosis, hyperkalemia, chronic kidney disease, heart failure, and health disparities. We prioritized randomized controlled trials, prespecified pooled analyses, mechanistic studies, and current guidelines, and hand-searched reference lists. No quantitative synthesis was performed. Findings: Aldosterone-MR signaling promotes fibrosis, inflammation, oxidative stress, and adverse remodeling across cardiovascular and renal tissues, and may be particularly relevant in low-renin, salt-sensitive phenotypes observed more frequently, on average, among Black patients. Randomized trials support MR antagonists (MRAs) in resistant hypertension, heart failure, and diabetic CKD; however, MRAs are often introduced late, when reduced renal function raises hyperkalemia risk and limits preventive benefit. Conclusion: In selected higher-risk patients with preserved renal function and controlled potassium, earlier MR antagonism may warrant prospective evaluation as a tissue-protective, disparity-reducing strategy. This framework is hypothesis-generating and is intended to stimulate research, not to alter current guideline-directed therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.